TELA Bio (TELA) Cash from Operations Growth (3y) (2021 - 2026)

TELA Bio (TELA) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Abbott Laboratories 152.92 Bn 146.27 Bn 6.27 Bn 4.78%
2 Stryker 119.50 Bn 116.62 Bn 3.81 Bn 9.30%
3 Medtronic 102.71 Bn 94.54 Bn 5.76 Bn 20.35%
4 Boston Scientific 69.72 Bn 68.51 Bn 3.61 Bn 22.35%
5 Edwards Lifesciences 49.24 Bn 45.57 Bn 1.29 Bn -48.14%
6 GE HealthCare Technologies 29.74 Bn 27.67 Bn 1.98 Bn -14.75%
7 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 0.50%
8 Dexcom 28.96 Bn 27.84 Bn 750.30 Mn 50.11%
9 Steris 20.31 Bn 19.88 Bn 697.10 Mn 15.83%
10 TELA Bio 49.36 Mn 9.81 Mn 12.52 Mn 1.18%

Historic Data

Download Data
DateValue
Mar 31, 2026 1.18%
Dec 31, 2025 23.74%
Sep 30, 2025 9.24%
Jun 30, 2025 12.22%
Mar 31, 2025 2.31%
Dec 31, 2024 7.73%
Sep 30, 2024 -10.65%
Jun 30, 2024 -23.86%
Mar 31, 2024 -18.77%
Dec 31, 2023 -15.87%
Sep 30, 2023 -23.60%
Jun 30, 2023 -21.02%
Mar 31, 2023 -16.57%
Dec 31, 2022 -15.20%
Sep 30, 2022 -12.61%
Jun 30, 2022 -30.94%
Mar 31, 2022 -10.28%
Dec 31, 2021 -18.49%